risankizumab/lutikizumab (ABBV-166) / AbbVie - LARVOL DELTA

Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease (clinicaltrials.gov) - P2 | N=540 | Recruiting | Sponsor: AbbVie | Trial completion date: Aug 2028 ➔ Jan 2030 | Trial primary completion date: Dec 2027 ➔ Jan 2030

Trial completion date • Trial primary completion date • Crohn's disease • Gastroenterology • Immunology • Inflammatory Bowel Disease